BR112021008832A2 - Proteínas de núcleo de mininucleossoma e uso em distribuição de ácido nucleico - Google Patents
Proteínas de núcleo de mininucleossoma e uso em distribuição de ácido nucleico Download PDFInfo
- Publication number
- BR112021008832A2 BR112021008832A2 BR112021008832-6A BR112021008832A BR112021008832A2 BR 112021008832 A2 BR112021008832 A2 BR 112021008832A2 BR 112021008832 A BR112021008832 A BR 112021008832A BR 112021008832 A2 BR112021008832 A2 BR 112021008832A2
- Authority
- BR
- Brazil
- Prior art keywords
- mininucleosome
- domain
- nucleic acid
- modified polypeptide
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862757683P | 2018-11-08 | 2018-11-08 | |
US62/757,683 | 2018-11-08 | ||
PCT/US2019/060119 WO2020097235A1 (en) | 2018-11-08 | 2019-11-06 | Mini-nucleosome core proteins and use in nucleic acid delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021008832A2 true BR112021008832A2 (pt) | 2021-08-31 |
Family
ID=70611091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021008832-6A BR112021008832A2 (pt) | 2018-11-08 | 2019-11-06 | Proteínas de núcleo de mininucleossoma e uso em distribuição de ácido nucleico |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210395303A1 (ja) |
EP (1) | EP3877526A4 (ja) |
JP (2) | JP2022512977A (ja) |
KR (1) | KR20210108952A (ja) |
CN (1) | CN113423834A (ja) |
AU (1) | AU2019376641A1 (ja) |
BR (1) | BR112021008832A2 (ja) |
CA (1) | CA3118146A1 (ja) |
IL (1) | IL282982A (ja) |
MX (1) | MX2021005313A (ja) |
SG (1) | SG11202104354TA (ja) |
WO (1) | WO2020097235A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102470059B1 (ko) * | 2018-05-18 | 2022-11-22 | 에프. 호프만-라 로슈 아게 | 큰 핵산의 표적화된 세포내 전달 |
IL297250A (en) * | 2020-04-13 | 2022-12-01 | Summation Bio Inc | Modified mininucleosome core proteins and use in nucleic acid delivery |
CA3226457A1 (en) * | 2021-07-30 | 2023-02-02 | Amy WALKER | Nanoparticles and peptides for the delivery of cargos to muscle cells |
EP4124345A1 (en) * | 2021-07-30 | 2023-02-01 | 4basebio UK Ltd | Nanoparticles for muscle delivery |
WO2023014724A2 (en) * | 2021-08-03 | 2023-02-09 | Summation Bio, Inc. | Scaffold matrix attachment regions for gene therapy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5670347A (en) * | 1994-05-11 | 1997-09-23 | Amba Biosciences Llc | Peptide-mediated gene transfer |
WO1996040958A1 (en) * | 1995-06-07 | 1996-12-19 | Baylor College Of Medicine | Nucleic acid transporters for delivery of nucleic acids into a cell |
WO1996041606A2 (en) * | 1995-06-08 | 1996-12-27 | Therexsys Limited | Improved pharmaceutical compositions for gene therapy |
AU1029099A (en) * | 1997-10-10 | 1999-05-03 | Aventis Pharma Deutschland Gmbh | Transfection system for the transfer of nucleic acids into cells |
KR20040011480A (ko) * | 2001-03-22 | 2004-02-05 | 덴드레온 샌 디에고 엘엘씨 | 세린 프로테아제 cvsp14를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법 |
DK1594973T3 (da) * | 2003-02-10 | 2012-02-13 | Max Delbrueck Centrum | Transposonbaseret målretningssystem |
JP4521519B2 (ja) * | 2003-05-26 | 2010-08-11 | 学校法人慶應義塾 | 部分ヒストンテイル型イムノポーター |
CA2528830A1 (en) * | 2003-06-10 | 2004-12-16 | Toolgen, Inc. | Transducible dna-binding proteins |
US7205387B2 (en) * | 2003-08-28 | 2007-04-17 | Agency For Science, Technology And Research | Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist |
US20060018911A1 (en) * | 2004-01-12 | 2006-01-26 | Dana Ault-Riche | Design of therapeutics and therapeutics |
PL391627A1 (pl) * | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
US9746475B2 (en) * | 2011-03-14 | 2017-08-29 | University Of Southern California | Antibody and antibody mimetic for visualization and ablation of endogenous proteins |
US10407469B2 (en) * | 2016-04-01 | 2019-09-10 | Northwestern University | Programmable polypeptide and nucleic acid nanoparticles |
AU2017378427A1 (en) * | 2016-12-14 | 2019-06-20 | Ligandal, Inc. | Methods and compositions for nucleic acid and protein payload delivery |
-
2019
- 2019-11-06 JP JP2021525131A patent/JP2022512977A/ja active Pending
- 2019-11-06 AU AU2019376641A patent/AU2019376641A1/en active Pending
- 2019-11-06 BR BR112021008832-6A patent/BR112021008832A2/pt unknown
- 2019-11-06 MX MX2021005313A patent/MX2021005313A/es unknown
- 2019-11-06 EP EP19881972.4A patent/EP3877526A4/en active Pending
- 2019-11-06 KR KR1020217017367A patent/KR20210108952A/ko not_active Application Discontinuation
- 2019-11-06 CA CA3118146A patent/CA3118146A1/en active Pending
- 2019-11-06 US US17/292,292 patent/US20210395303A1/en active Pending
- 2019-11-06 CN CN201980077659.8A patent/CN113423834A/zh active Pending
- 2019-11-06 SG SG11202104354TA patent/SG11202104354TA/en unknown
- 2019-11-06 WO PCT/US2019/060119 patent/WO2020097235A1/en unknown
-
2021
- 2021-05-06 IL IL282982A patent/IL282982A/en unknown
-
2023
- 2023-12-25 JP JP2023217957A patent/JP2024029097A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202104354TA (en) | 2021-05-28 |
JP2022512977A (ja) | 2022-02-07 |
WO2020097235A1 (en) | 2020-05-14 |
CA3118146A1 (en) | 2020-05-14 |
MX2021005313A (es) | 2021-10-13 |
KR20210108952A (ko) | 2021-09-03 |
IL282982A (en) | 2021-06-30 |
CN113423834A (zh) | 2021-09-21 |
US20210395303A1 (en) | 2021-12-23 |
EP3877526A1 (en) | 2021-09-15 |
AU2019376641A1 (en) | 2021-05-27 |
JP2024029097A (ja) | 2024-03-05 |
EP3877526A4 (en) | 2023-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nakase et al. | Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides | |
BR112021008832A2 (pt) | Proteínas de núcleo de mininucleossoma e uso em distribuição de ácido nucleico | |
ES2627822T3 (es) | Péptidos de penetración celular para administración intracelular de moléculas | |
Snyder et al. | Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids invivo | |
de Figueiredo et al. | Cell‐penetrating peptides: a tool for effective delivery in gene‐targeted therapies | |
Meng et al. | Enhanced gene transfection efficiency by use of peptide vectors containing laminin receptor-targeting sequence YIGSR | |
KR101647804B1 (ko) | 신규 세포투과 펩타이드 및 이의 용도 | |
US20210290539A1 (en) | Engineered hemichannels, engineered vesicles, and uses thereof | |
WO2006073446A2 (en) | Peptide-mediated protein transduction into cells the hematopoietic lineage | |
Kamei et al. | Noncovalent Strategy with Cell-Penetrating Peptides to Facilitate the Brain Delivery of Insulin through the Blood–Brain Barrier | |
CA2406352A1 (en) | Peptide conjugates for drug delivery | |
BR112019023116A2 (pt) | fragmentos de cdnf e manf do terminal c, composições farmacêuticas que os compreendem e usos dos mesmos | |
TW201927825A (zh) | Cdkl5 表現變體和cdkl5 融合蛋白 | |
Sakamoto et al. | Artificial nanocage formed via self-assembly of β-annulus peptide for delivering biofunctional proteins into cell interiors | |
Toro et al. | Intracellular delivery of purine nucleoside phosphorylase (PNP) fused to protein transduction domain corrects PNP deficiency in vitro | |
US20230203507A1 (en) | Modified mini-nucleosome core proteins and use in nucleic acid delivery | |
ES2957688T3 (es) | Construcción génica suicida doble e inducible y su uso en terapia génica | |
Ciobanasu et al. | Cell‐Penetrating Peptides Targeting and Distorting Biological Membranes | |
Langel | Clinical Trials and Commercialization Using CPPs | |
US20230128981A1 (en) | Cd24-loaded vesicles for treatment of cytokine storm and other conditions | |
US20240197896A1 (en) | Synthetic peptide shuttle agent bioconjugates for intracellular cargo delivery | |
US20230383291A1 (en) | Peptide-based transduction of non-anionic polynucleotide analogs for gene expression modulation | |
CN116615205A (zh) | 用于基因表达调节的非阴离子多核苷酸类似物的基于肽的转导 | |
KR20240035722A (ko) | 세포 내 형질주입을 위한 신규한 폴리펩타이드 조성물 | |
CN116615227A (zh) | 适用于Cas9-RNP和其他核蛋白负荷的转导的最小长度的穿梭剂肽及其变体 |